Education
About Us
Working with TipRanks
Follow Us
Exelixis (EXEL)
NASDAQ:EXEL
Earnings Data
Report Date
Aug 12, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
0.6Last Year’s EPS
0.77Same Quarter Last Year
Moderate Buy
Based on 16 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 13, 2025
|% Change Since: 14.72%
|Next Earnings Date:Aug 12, 2025
Earnings Call Sentiment|Positive
Exelixis demonstrated strong financial and operational performance in Q1 2025, highlighted by significant revenue growth and regulatory approvals. Despite some challenges with operational expenses and the discontinuation of XL495, the company raised its financial guidance and showed promising pipeline progress.Company Guidance
During the Exelixis First Quarter 2025 Financial Results Conference Call, the company provided updated guidance reflecting strong performance and future expectations. The US cabo franchise saw a 36% year-over-year increase in net product revenues, reaching $513 million, while global cabo revenues hit $680 million. This robust performance led to an upward revision of the 2025 financial guidance, with net product revenues now projected between $2.05 billion and $2.15 billion, and total revenues between $2.25 billion and $2.35 billion, each increased by $100 million. Exelixis attributed its success to the growing demand for CABOMETYX, especially following its regulatory approval for neuroendocrine tumors, and highlighted strategic advancements in their pipeline, including pivotal trials for zanzalintinib in various cancer types. The company also reported a GAAP net income of $159.6 million and a non-GAAP net income of $179.6 million for the quarter, with a strong balance sheet featuring $1.65 billion in cash and marketable securities.Strong Financial Performance
Exelixis reported total revenues of approximately $555 million for Q1 2025, with cabozantinib franchise net product revenues at $513.3 million, marking a 36% year-over-year increase.
US CABOMETYX Growth
The CABOMETYX US Business demonstrated strong growth with net product revenues increasing to $513 million from $378 million year-over-year, reflecting a 36% increase.
Regulatory Approval for CABOMETYX
CABOMETYX received US regulatory approval for use in neuroendocrine tumors, achieving this milestone ahead of the assigned PDUFA date.
Raised Financial Guidance
Exelixis increased its 2025 full-year financial guidance for net product revenues and total revenues by $100 million due to strong Q1 performance.
Pipeline Progress
Exelixis advanced new molecules from its pipeline, including zanza, with pivotal trial milestones anticipated in the second half of 2025.
EXEL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
EXEL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 13, 2025 | $36.95 | $44.65 | +20.84% |
Feb 11, 2025 | $32.81 | $32.80 | -0.03% |
Oct 29, 2024 | $28.73 | $32.44 | +12.91% |
Aug 06, 2024 | $23.45 | $26.52 | +13.09% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Exelixis (EXEL) report earnings?
Exelixis (EXEL) is schdueled to report earning on Aug 12, 2025, TBA Not Confirmed.
What is Exelixis (EXEL) earnings time?
Exelixis (EXEL) earnings time is at Aug 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is EXEL EPS forecast?
EXEL EPS forecast for the fiscal quarter 2025 (Q2) is 0.6.